Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aadi Bioscience, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
AADI
Nasdaq
2830
aadibio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aadi Bioscience, Inc.
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
- Feb 5th, 2025 9:05 pm
Aadi Bioscience Leads 3 Promising US Penny Stocks
- Dec 23rd, 2024 12:09 am
Aadi Bioscience’s Strategic Agreements and Funding Moves
- Dec 21st, 2024 11:31 am
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
- Dec 19th, 2024 11:30 pm
US Penny Stocks Under $90M Market Cap To Watch
- Nov 12th, 2024 8:07 pm
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
- Nov 6th, 2024 1:00 pm
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
- Aug 20th, 2024 9:00 pm
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update
- Aug 7th, 2024 12:00 pm
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
- Jul 31st, 2024 8:05 pm
We're Keeping An Eye On Aadi Bioscience's (NASDAQ:AADI) Cash Burn Rate
- Jul 31st, 2024 12:56 pm
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
- May 29th, 2024 8:05 pm
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
- May 23rd, 2024 9:30 pm
Aadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To Know
- May 11th, 2024 12:08 pm
Analysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue Forecasts
- May 10th, 2024 10:19 am
Aadi Bioscience First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)
- May 9th, 2024 10:13 am
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
- May 8th, 2024 12:00 pm
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
- May 1st, 2024 12:00 pm
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
- Apr 9th, 2024 12:00 pm
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
- Mar 17th, 2024 12:00 pm
Aadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)
- Mar 14th, 2024 10:36 am
Scroll